
eczema

X
Incyte gets much-needed boost as eczema cream trial hits target
https://pharmaphorum.com/news/incyte-gets-much-needed-boost-as-eczema-cream-trial-hits-target/

X
Sanofi’s Dupixent funded in Wales and Scotland for adolescents with eczema
https://pharmaphorum.com/news/sanofis-dupixent-funded-in-wales-and-scotland-for-adolescents-with-eczema/

X
Novartis’ $100m bet on eczema drug fails as MOR106 development ends
https://pharmaphorum.com/news/novartis-100m-bet-on-eczema-drug-fails-as-mor106-development-ends/

X
Sanofi’s eczema drug gets EU approval to treat adolescents
https://pharmaphorum.com/news/sanofi-eczema-drug-gets-eu-approval-adolescents/

X
Almirall gets in on the eczema action
https://pharmaphorum.com/views-analysis-market-access/almirall-gets-in-on-the-eczema-action/

X
Patient Insights: Severe psoriasis & eczema
https://pharmaphorum.com/views-analysis-patients/patient-insights-severe-psoriasis-eczema/

X
FDA approves Sanofi/Regeneron’s Dupixent in asthma
https://pharmaphorum.com/news/fda-approves-sanofi-regenerons-dupixent-in-asthma/

Sanofi showcases eczema data ahead of EU decision
Dupixent predicted to be blockbuster for Sanofi
X
Sanofi showcases eczema data ahead of EU decision
https://pharmaphorum.com/news/dupixent-data-sanofi-ahead-eu-decision/
1 2